Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Anti-Parkinson Drugs Market From 2025 To 2029?
The market for anti-Parkinson’s medications has recently seen significant expansion. It is projected to increase from $10.39 billion in 2024 to $10.96 billion in 2025, at a 5.5% compound annual growth rate (CAGR). The reasons for the growth during the historical period can be attributed to factors such as the aging population, rising incidence of the disease, improved healthcare infrastructure and progressive advancements in research.
Predictions suggest a robust expansion in the anti-parkinson drugs market over the approaching years. By 2029, the market size is forecasted to reach $13.48 billion, growing at a compound annual growth rate (CAGR) of 5.3%. This significant surge in the forecast period can be ascribed to several contributing factors such as heightened public awareness, advancements in biotechnology, and newly emerging markets. On the horizon, the forecast period is likely to experience certain key trends including investments in research and development, a rise in personalized medicine, the advent of disease-modifying therapies, increased focus on drug repurposing, the broadening reach of telemedicine and remote monitoring, the growth of biosimilars, and amplified research partnerships.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp
What Are the Core Market Drivers Propelling Growth in the Anti-Parkinson Drugs Industry?
The rise in the elderly population coupled with escalating instances of Parkinson’s disease (PD) are anticipated to fuel the demand within the anti-Parkinson drugs market. PD is typically witnessed in individuals above 60 years of age. For example, findings from the World Health Organization in October 2022, revealed that a global health agency from the United States predicted that by 2030, 1 in every 6 individuals globally will be aged 60 or older. Furthermore, by 2050, the number of people in this age bracket is expected to double to 2.1 billion. Consequently, the growth of the anti-Parkinson drugs market is spurred on by the expanding geriatric population.
How Is the Anti-Parkinson Drugs Market Segmented?
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp
Which Regions Are Driving the Next Phase of the Anti-Parkinson Drugs Market Growth?
North America was the largest region in the anti-Parkinson drugs market in 2024. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Key Market Trends and Innovations Are Shaping the Future of the Anti-Parkinson Drugs Industry?
Leading companies in the anti-Parkinson drugs market are directing their efforts towards creating advanced therapeutic solutions such as motor fluctuations and dyskinesia, aiming to improve symptom management and reduce side effects. Such conditions often add to the complexities of Parkinson’s disease treatments, impacting the patient’s quality of life. For instance, in January 2024, US pharmaceutical company AbbVie Inc. introduced PRODUODOPA. This product, also known as foslevodopa/foscarbidopa, is a first-of-its-kind subcutaneous 24-hour infusion therapy for addressing severe motor fluctuations and dyskinesia in cases of advanced Parkinson’s disease when other treatments prove ineffective. PRODUODOPA provides a continuous supply of levodopa, which could potentially enhance ‘on’ time and better symptom control.
View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
How Is the Anti-Parkinson Drugs Market Defined and What Are Its Core Parameters?
Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson’s disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic’s negative effects.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model